Altman Peter purchased $415 of BCDA

Altman Peter (President and CEO) purchased 500 shares of BioCardia, Inc. (BCDA) at $0.83 on 2026-07-17.

Original reporting
SEC EDGAR · Altman Peter
Published Jul 20, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 12:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BCDA
Bullish
medium confidence
Mentioned
$BCDA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BCDABullishLow
01

Why it matters

This is a primary-source insider buy by the CEO, but the disclosed size is modest and the filing contains no new business or financial information.

02

Market read

Traders may view the CEO’s open-market purchase as a small positive sentiment datapoint, but it is unlikely to drive a fundamental repricing without additional catalysts.

03

What to watch

The filing does not include any accompanying corporate update, guidance, or material event; without context on prior transactions, signal strength is limited.

Relevance 4/10Novelty 3/10Timing: Form 4 filed July 20, covering a July 17 purchase.

Background

The article is a SEC Form 4 insider transaction disclosure for BioCardia, Inc. (BCDA).

Company-level read

Ticker impact

$BCDABullishMedium confidence
Context

BioCardia CEO Altman Peter bought 500 shares in an open-market transaction at $0.8300/share, disclosed via Form 4 filed July 20.

Expected impact

Likely limited near-term price impact; any effect would be incremental sentiment rather than a catalyst.

Evidence & confidence

Form 4 confirms the transaction details (shares, price, total value) and insider role, but the article provides no operational or financial change that would re-rate the business.

Market effects

No sector read-through is provided beyond a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine, tax- or compensation-related, and the small $415 value may not signal a meaningful change in outlook.

Key entities

  • BioCardia, Inc.

    Company whose CEO insider purchase is disclosed on Form 4.

  • Altman Peter

    President and CEO who purchased 500 shares at $0.8300/share.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BCDAMed

BioCardia Inc (BCDA) (Q3 2026) Earnings Call Highlights: Japan Shonin Submission Advances

BioCardia Inc (BCDA) reported Q3 2026 earnings, highlighting progress in Japan's Shonin submission for CardiAMP Cell Therapy, expected within months. CEO Peter Altman discussed partnerships, regulatory pathways, and clinical trial updates. The company reported $1.7M in net cash used in operations, with $2.2M in cash reserves. Key catalysts include FDA feedback on the Helix catheter system and potential gene therapy partnerships.

$BCDAMedAI 8/10

BioCardia’s CardiAMP Completes Japan Pre-Market Consultation, First Cardiac Cell Therapy to Do So

BioCardia (BCDA) completed Japan's PMDA consultation for its CardiAMP Cell Therapy System, positioning it for a marketing approval application. The therapy, which uses a patient's own bone marrow cells, aims to treat heart damage. BioCardia targets a formal submission by late 2026 and commercial revenue by 2028. The company's Phase 3 trial showed significant improvements in a subgroup of patients with elevated NTproBNP levels, which PMDA has reviewed positively.

$BCDAMed

BioCardia Completes Clinical Consultation Process with Japan's PMDA for CardiAMP Cell Therapy System, Advancing Toward Submission of Marketing Approval…

BioCardia, Inc. (BCDA) filed an SEC Form 8-K — Other Events. Exhibit 99.1 BioCardia Completes Clinical Consultation Process with Japan's PMDA for CardiAMP Cell Therapy System, Advancing Toward Submission of Marketing Approval Application SUNNYVALE, Calif., November 6, 2026 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. (NASDAQ: BCDA) , a global le

$BCDAMedAI 8/10

BioCardia Advances Helix Catheter Toward FDA Marketing Clearance

BioCardia (BCDA) submitted a revised De Novo pre-submission package to the FDA for its Helix catheter, following feedback. The FDA accepted the submission and expects review, feedback, and a meeting in Q4 2026. The catheter is designed for delivering therapeutic agents to heart muscle and has clinical safety data from 15 trials. FDA clearance could expand partnership opportunities for BCDA.